Human stem cells

• US 4,714,680 A
• Filed: 02/06/1984
• Issued: 12/22/1987
• Est. Priority Date: 02/06/1984
• Status: Expired due to Term

• Current Assignee: Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: Civin, Curt I.
• Primary Examiner(s): Wiseman, Thomas G.
• Assistant Examiner(s): Weimar, Elizabeth C.
• Application Number:
  US06/670,740
• Time in Patent Office: 1,415 Days
• Field of Search: 435/240, 435/241, 435/7
• US Class Current: 435/347
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants

Abstract

Monoclonal antibodies that recognize a stage-specific antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as theraputic methods employing the cell suspensions.

Claims

1. A suspension of human cells comprising pluripotent lympho-hematopoietic stem cells substantially free of mature lymphoid and myeloid cells.

2. The cell suspension of claim 1 further comprising colony-forming cells for granulocytes/monocytes (CC-GM), colony-forming cells for erythrocytes (BFU-E), colony-forming cells for eosinophils (CFC-Eo), multipotent colony-forming cells (CFC-GEMM), and immature lymphoid precursor cells.

3. The cell suspension of claim 1 substantially free of cells without a cell-surface antigen recognized by the monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-8483.

4. A suspension of human cells from blood comprising pluripotent lympho-hematopoietic stem cells substantially free of mature lymphoid and myeloid cells.

5. A suspension of human cells from marrow or blood comprising cells having a cell-surface antigen recognized by the antibody produced by the hybridoma deposited under ATCC Accession No. HB-8483 and substantially free of cells that do not have a cell-surface antigen recognized by said antibody, said suspension having the ability to restore the production of lymphold and hematopoietic cells to a human lacking said production.